Orion Oyj Orion\'s and Bayer\'s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

Orion Oyj: Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

16:53 EST 14 Feb 2019 | FinanzNachrichten

Orion Corporation Press ReleaseCommunications 14 February 2019 at 11.45 p.m. EET Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of pro...

More From BioPortfolio on "Orion Oyj: Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial"